TennCare - As enacted, authorizes the bureau to provide coverage and treatment on behalf of an enrollee for the diagnosis, including genetic testing, and treatment of Kleefstra syndrome in the same manner and to the same extent that the bureau provides coverage for autism spectrum disorder, Trisomy 21 or Down syndrome, and other similar or related genetic disorders, when determined to be medically necessary. - Amends TCA Title 56 and Title 71.

HB 502 expands TennCare coverage to include diagnosis (including genetic testing) and treatment for Kleefstra syndrome, a rare genetic disorder affecting development and multiple body systems. It requires TennCare to provide this coverage in the same manner and extent as for autism spectrum disorder, Down syndrome (Trisomy 21), and other similar genetic disorders, when medically necessary. This applies to all enrolled individuals with Kleefstra syndrome and covers therapies, medications, assistive devices, and interventions aimed at improving quality of life. The law takes effect July 1, 2025, after being signed by the Governor in April 2025.